Crescent Biopharma, Inc. Revenue 2012–2025
Crescent Biopharma, Inc. annual/quarterly revenue history and growth rate from 2012 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Crescent Biopharma, Inc. revenue for the quarter ending March 31, 2026 was 1.0 M.
- Crescent Biopharma, Inc. revenue for the twelve months ending March 31, 2026 was 1.2 M, a 89.14% decrease year-over-year.
- Crescent Biopharma, Inc. annual revenue for 2025 was 10.8 M, a 108340.00% increase from 2023.
- Crescent Biopharma, Inc. annual revenue for 2023 was 10000, a 86.67% decrease from 2022.
- Crescent Biopharma, Inc. annual revenue for 2022 was 75000, a 93.53% decrease from 2021.
- Crescent Biopharma, Inc. annual revenue for 2021 was 1.2 M.
Crescent Biopharma, Inc. (CBIO) — Frequently Asked Questions
Crescent Biopharma, Inc. (CBIO) is a publicly traded US company. It has a market capitalization of $484M. In fiscal 2025 it reported revenue of $11M and net income of -$154M. Explore CBIO's stock price, financial statements, earnings history, margins and key ratios below.
What is Crescent Biopharma, Inc.'s market cap?
Crescent Biopharma, Inc. (CBIO) has a market capitalization of $484M.
What is the CBIO stock price?
CBIO trades at $17.57 (-2.39% on the day).
How much revenue does Crescent Biopharma, Inc. make?
Crescent Biopharma, Inc. reported revenue of $11M in fiscal 2025.
Is CBIO profitable?
In fiscal 2025, Crescent Biopharma, Inc. reported net income of -$154M.